IMR Press / FBL / Volume 26 / Issue 10 / DOI: 10.52586/4979
Open Access Commentary
Is miR therapeutic targeting still a miRage?
Show Less
1 Harvard Medical School, Boston, MA 02115, USA
2 Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
3 Harvard Stem Cell Institute, Cambridge, MA 02138, USA
4 Institute of Biomedical Technologies, National Research Council (CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy
*Correspondence:; (Elena Levantini)
Front. Biosci. (Landmark Ed) 2021, 26(10), 680–692;
Submitted: 20 August 2021 | Revised: 5 October 2021 | Accepted: 7 October 2021 | Published: 30 October 2021
Copyright: © 2021 The Author(s). Published by BRI.
This is an open access article under the CC BY 4.0 license (

Since the discovery of the first microRNA (miR), almost three decades ago, the roles played by miRs under normal and diseased settings have been widely investigated. miRs are found to play crucial roles in cancer initiation and progression, as well as towards therapy response mechanisms. Therefore, they are relevant and attractive targets for therapeutic development. Many preclinical studies have demonstrated their promise as future anti-cancer tools. Recently, increasing number of early phase clinical trials have emerged. In this Commentary, we will summarize the major discoveries within the miR research field and highlight the status quo of current miR-therapeutics, which has prominent potential of impacting future cancer regimens given their massive dysregulation in oncogenic processes.

RNA therapeutics
Fig. 1.
Back to top